During the past decade, Klinische Forschung Dresden GmbH conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 21 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 16 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinische Forschung Dresden GmbH" #1 sponsor was "Pfizer" with 6 trials, followed by "Allergan" with 4 trials sponsored, "Bayer" with 4 trials sponsored, "Shire" with 3 trials sponsored and "Amgen" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinische Forschung Dresden GmbH" #1 collaborator was "Bioskin GmbH" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "FGK Clinical Research GmbH" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Klinische Forschung Dresden GmbH" are "Psoriasis" (7 trials), "Gastroparesis" (4 trials), "Binge Eating Disorder" (3 trials), "Dermatitis, Atopic" (3 trials) and "Diabetes Mellitus" (3 trials). Many other conditions were trialed in "Klinische Forschung Dresden GmbH" in a lesser frequency.

Most popular intervention types in "Klinische Forschung Dresden GmbH" are "Drug" (34 trials), "Biological" (5 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Relamorelin" (3 trials), "Abrocitinib 200 mg" (2 trials), "CHS-0214" (2 trials) and "Etanercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinische Forschung Dresden GmbH" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Klinische Forschung Dresden GmbH". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Klinische Forschung Dresden GmbH, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Klinische Forschung Dresden GmbH, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".